Dynavax Technologies Corporation (NASDAQ: DVAX) is garnering attention in the healthcare sector, particularly among investors eyeing its promising potential upside. With a market capitalization of $1.82 billion, this biopharmaceutical company specializes in developing and commercializing vaccines such as HEPLISAV-B, aimed at preventing hepatitis B infections. The company’s innovative pipeline also includes vaccine candidates targeting the plague and shingles.

Despite a current share price of $15.50, Dynavax presents a significant opportunity for growth with a potential upside of 41.94%, according to analyst target price projections. The average target price is set at $22.00, with a range between $16.00 and $25.00. This suggests…